Massive Hematuria in Relation to the Use of Ticagrelor: Case Report

Major clinical benefits of antiplatelet therapy initiated after acute coronary syndrome (ACS) have been demonstrated in cardiovascular clinical trials and Dual antiplatelet therapy consisting of a P2Y12 receptor antagonist with aspirin is recommended as part of standard therapy for secondary protection. However, bleeding episodes that develop during antiplatelet therapy are significant problems. Ticagrelor is a newly developed reversible P2Y12 antagonist antiplatelet agent. This agent, which is part of standard antiplatelet therapy with aspirin, also causes additional bleeding risk. In this case; we present a case of massive hematuria which is a rare side effect due to use of ticagrelor which is used for a treatment after a non-ST-elevated myocardial infarction (NSTEMI) with a percutaneous coronary intervention. Keywords: Dual Antiplatelet Therapy; Hematuria; Hemorrhage; Ticagrelor